Patrick Leavey, M.D.

Patrick Leavey graduated from the Royal College of Surgeons in Ireland in 1986. He spent 4 years in Ireland as a junior house officer (Internal Medicine and Pediatrics), 2 years at Princess Margaret Hospital in Perth, Western Australia as a pediatric registrar and then came to the US to do his pediatric hematology/oncology fellowship at The Children’s Hospital Denver and University of Colorado Health Sciences Center in 1992. Dr. Leavey worked in the lab of Daniel Ambruso, M.D. for 4 years on projects related to the influence of G-CSF on granulocyte function and the exploration and identification of a novel neutrophil cytosolic protein.

Dr. Leavey joined the pediatric faculty at UT Southwestern Medical Center in 1998 where he is currently a Professor of Pediatrics and a Pediatric Oncologist at Children’s Health, Children’s Medical Center Dallas and Plano.

During his years of training Dr. Leavey became a member of the Royal College of Physicians of Ireland, a Fellow of the Royal Australasian College of Physicians and a Diplomate of Child Health from the National University of Ireland. He was granted a Doctorate in Medicine from the National University of Ireland, based on his work in the Ambruso laboratory. He is subspecialty board certified in Pediatric Hematology/Oncology by the American Board of Pediatrics.

Currently Dr. Leavey holds several leadership positions both regionally and nationally. He is the Associate Medical Director for Clinical Affairs, for the Pauline Allen Gill Center for Cancer and Blood Disorders and the Director of the Musculoskeletal Tumors Program at Children's Health. Dr. Leavey is the President of the American Society of Pediatric Hematology/Oncology and a member of their Board of Trustees and Executive committee. At the Children’s Oncology Group (COG), Dr. Leavey is a member of the Bone Sarcoma Committee, and he the institutional COG principal investigator for UT Southwestern Medical Center. Dr. Leavey serves on medical advisory boards for the Children’s Cancer Fund and The Clayton Dabney Foundation. 

Dr. Leavey hold several key positions in clinical and translational research. He is the physician lead for the clinical research office at the Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Health and he is the study chair for the COG international study for newly diagnosed patients with non-metastatic Ewing Sarcoma (AEWS1031). He receives grant funding as a principal investigator from the Cancer Prevention Research Institute of Texas (CPRIT; RP150164) and the National Cancer Institute (R21 PA-16-252), for his investigator initiated translational research programs in childhood sarcoma.

Dr. Leavey was included again in D Magazine's Best Doctors list for 2018.

Medical School

Royal College of Surgeons (1986)

Internship

Beaumont Hospital (1987), General Surgery

Residency

St. Vincents Hospital - Dublin Ireland (1989), Internal Medicine

Fellowship

University of Colorado Health Sciences Center (1996), Pediatric Hematology/oncology

Residency

Children's Hospital of Denver (1998), Pediatrics

• Development of a novel biomarker for patients with Osteosarcoma using advanced imaging, digital histology and automated learning tools
• Development of advances in therapy for children with sarcoma
• To leverage techniques detailing metabolic reprogramming to develop novel biomarkers and therapeutic targets for fusion positive sarcoma

Featured Publications

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD, Br. J. Cancer 2019 Apr 120 8 869

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N Eur. J. Cancer 2019 Mar 109 36-50

Viable and necrotic tumor assessment from whole slide images of osteosarcoma using machine-learning and deep-learning models.

Arunachalam HB, Mishra R, Daescu O, Cederberg K, Rakheja D, Sengupta A, Leonard D, Hallac R, Leavey P, PLoS ONE 2019 14 4 e0210706

Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.

Armstrong AE, Walterhouse DO, Leavey PJ, Reichek J, Walz AL Pediatr Blood Cancer 2018 Oct e27493

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JMM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG J Thorac Oncol 2018 Sep

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD Br. J. Cancer 2018 Aug

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.

Hanna JA, Garcia MR, Lardennois A, Leavey PJ, Maglic D, Fagnan A, Go JC, Roach J, Wang YD, Finkelstein D, Hatley ME Oncogene 2018 Jan

The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1-Current state of the workforce.

Hord J, Shah M, Badawy SM, Matthews D, Hilden J, Wayne AS, Salsberg E, Leavey PS Pediatr Blood Cancer 2017 Oct

Convolutional Neural Network for Histopathological Analysis of Osteosarcoma.

Mishra R, Daescu O, Leavey P, Rakheja D, Sengupta A J. Comput. Biol. 2017 Oct

Hope as a Predictor of Anxiety and Depressive Symptoms Following Pediatric Cancer Diagnosis.

Germann JN, Leonard D, Heath CL, Stewart SM, Leavey PJ J Pediatr Psychol 2017 Jul

 Featured Books

Histopathological Diagnosis for Viable and Non-viable Tumor Prediction for Osteosarcoma Using Convolutional Neural Network. In Bioinformatics Research and Verlag

Mishra R, Daescu O, Leavey P, Rakheja D, Sengupta A. (2017). Springer

• Best Pediatric Specialists/Doctors in Dallas
  D Magazine (2010-2011) (2013) (2015-2016) (2018)
• Faculty Teaching Award
  UT Southwestern and Children's Medical Center (2009)
• Medical Achievement Award
  Little Mo Award - awarded by Wipe out Kids Cancer (2008)
• Elected to the Society for Pediatric Research
  (2006)
• Achievement Award
  ’Gift of Giving Back Award’ first such award given by the Clayton Dabney Foundation for Kids with Cancer (2005)

• American Society of Clinical Oncology (2012)
• Society for Pediatric Research (2006)
• American Society of Pediatric Hematology/Oncology (2004)
• Children's Oncology Group (2002)
• Connective Tissue Oncology Society
• Dallas County Medical Society and Texas Medical Association